Apalutamide and Bosentan: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A induction can reduce bosentan exposure.
Clinical significance and safety
Apalutamide and Bosentan: The inducing medicine may reduce the response to bosentan. A pulmonary-hypertension specialist should review treatment and monitor response after an inducer starts, changes or stops. Do not alter medicines yourself. This exposure concern does not establish treatment failure in every person.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.